Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Feedback from HCPs and PwD about group GLP-1 RA starts including the following considerations: Group GLP-1 RA group starts do have their place in increasing prescribing and access to GLP-1 RA therapies for PwD who could benefit potentially most
In the lungs, GLP-1RAs attenuate acute lung injury by maintaining alveolar-capillary barrier function, reducing neutrophil infiltration, and promoting surfactant protein expression, potentially through suppression of NLRP3 inflammasome activity
A sensitivity analysis accounting for factors such as demographics, starting BMI classification, residence in a socially vulnerable area, comorbidities, and baseline HbA1c level also found that patients on GLP-1s were more likely to experience weight loss and to reduce their HbA1c levels
Available from: Accessed on 21/012026 Soliman N, Moisset X, Ferraro MC, et al
For more information on Numerators GLP-1 insights and offerings, head over to our GLP-1 Research Hub or get in touch with our team.
Sikiric, R
US$ 26.97
US$ 21.87
US$ 21.68
US$ 22.48
